Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) Shares Outstanding (Diluted Average) (2020 - 2025)

Traws Pharma (TRAW) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $8.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 667.07% to $8.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.0 million, a 667.07% increase, with the full-year FY2024 number at $1.6 million, up 84.94% from a year prior.
  • Shares Outstanding (Diluted Average) was $8.0 million for Q3 2025 at Traws Pharma, up from $7.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $21.0 million in Q2 2023 to a low of $839243.0 in Q3 2023.
  • A 5-year average of $11.4 million and a median of $14.6 million in 2021 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): plummeted 95.99% in 2023, then surged 757.17% in 2025.
  • Traws Pharma's Shares Outstanding (Diluted Average) stood at $16.8 million in 2021, then increased by 24.22% to $20.9 million in 2022, then tumbled by 95.98% to $839554.0 in 2023, then soared by 84.94% to $1.6 million in 2024, then skyrocketed by 415.65% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Shares Outstanding (Diluted Average) are $8.0 million (Q3 2025), $7.6 million (Q2 2025), and $7.2 million (Q1 2025).